Migraine: Current therapeutic targets and future avenues

Current Vascular Pharmacology

Volumn 4, Issue 2, 2006, Pages 117-128

  Arulmozhi, D K ^a,b   Veeranjaneyulu, A ^a   Bodhankar, S L ^b  

^a LUPIN LIMITED   (India)

^b BHARATI VIDYAPEETH DEEMED UNIVERSITY   (India)

Author keywords

Headache; Migraine; Serotonin; Vasodilatation

Indexed keywords

ACETYLSALICYLIC ACID; AMITRIPTYLINE; ANTIMIGRAINE AGENT; ATENOLOL; BUTALBITAL; BUTORPHANOL; CODEINE; CYPROHEPTADINE; DEXAMETHASONE; DICLOFENAC; DIHYDROERGOTAMINE; DILTIAZEM; ERGOTAMINE TARTRATE; FLURBIPROFEN; IBUPROFEN; ISOMETHEPTENE; KETOPROFEN; KETOROLAC; MEFENAMIC ACID; METOCLOPRAMIDE; NAPROXEN; NARATRIPTAN; PARACETAMOL; PETHIDINE; PROCHLORPERAZINE; RIZATRIPTAN; SUMATRIPTAN; UNINDEXED DRUG; VALPROATE SEMISODIUM; ZOLMITRIPTAN; SEROTONIN RECEPTOR;

AKATHISIA; BRADYCARDIA; CONFUSION; DEPRESSION; DIARRHEA; DIZZINESS; DREAM; DROWSINESS; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG METABOLISM; DYSTONIA; EDEMA; FATIGUE; FLUID RETENTION; GASTROINTESTINAL IRRITATION; GASTROINTESTINAL SYMPTOM; HAIR LOSS; HEADACHE; HUMAN; HYPOTENSION; MEMORY DISORDER; METABOLIC DISORDER; MIGRAINE; MUSCLE CRAMP; NAUSEA; NEUROGENIC INFLAMMATION; PARESTHESIA; PATHOPHYSIOLOGY; RASH; REVIEW; SEDATION; SEXUAL DYSFUNCTION; SEXUAL FUNCTION; SIDE EFFECT; SLEEP DISORDER; SWEATING; TREMOR; UNSPECIFIED SIDE EFFECT; URINE RETENTION; WEIGHT GAIN; XEROSTOMIA; DRUG EFFECT; PAIN;

HUMANS; MIGRAINE DISORDERS; PAIN; RECEPTORS, SEROTONIN;

EID: 33646059197     PISSN: 15701611     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016106776359853     Document Type: Review

References (101)

1. Silberstein SD. Migraine. Lancet 2004; 363: 381-91.
2. International Headache Society. International classification of headache disorders. Cephalalgia 2004; 24 (Sup.1): 1-160.
3. Olesen J, Lipton RB. Migraine classification and diagnosis. International Headache Society criteria. Neurology 1994; 44: S6-10.
4. Michel P, Henry P, Letenneur L, Jogeix M, Corson A, Dartigues JF. Diagnostic screen for assessment of the IHS criteria for migraine by general practitioners. Cephalalgia 1993; 13 (Suppl 12): 54-9.
5. Lance JW. Headache and face pain. Med J Aust 2000; 172: 450-5.
6. Rasmussen BK, Jensen R, Schroll M, Olesen J. Interrelations between migraine and tension-type headache in the general population. Arch Neurol 1992; 49: 914-8.
7. Rasmussen BK, Olesen J. Migraine with aura and migraine without aura: an epidemiological study. Cephalalgia 1992; 12: 221-8.
8. Launer LJ, Terwindt GM, Ferrari MD. The prevalence and characteristics of migraine in a population-based cohort: the GEM study. Neurology 1999; 53: 537-42.
9. Menken M, Munsat TL, Toole JF. The global burden of disease study: implications for neurology. Arch Neurol 2000; 57: 418-20.
10. Goadsby PJ. Migraine: selecting treatments now and making requests for the future? Curr Med Res Opin 2001; 17: S98-9.
11. May A, Goadsby PJ. The trigeminovascular system in humans: pathophysiological implications for primary headache syndromes of neural influences on the cerebral circulation. J Cereb Blood Flow Metab 1999; 19: 115-127.
12. 2+ channel gene CACNL1A4. Cell 1996; 87: 543-52.
13. Terwindt GM, Ophoff RA, van Eijk R, Vergouwe MN, Haan J, Frants RR, et al. Involvement of the CACNA1A gene containing region on 19p13 in migraine with and without aura. Neurology 2001; 56: 1028-32.
14. Zwetsloot CP, Caekebeke JF, Jansen JC, Odink J, Ferrari MD. Blood flow velocity changes in migraine attacks-a transcranial Doppler study. Cephalalgia 1991; 11: 103-7.
15. Vraamark T, Waldemar G, Paulson OB. Differential effects of migraine drugs on cerebral blood flow autoregulation. Cephalalgia 1998; 18: 306-12.
16. Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 1993; 33: 48-56
17. Moskowitz MA. Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine. Trends Pharmacol Sci 1992; 13: 307-11.
18. Pearce JM. Migraine: a cerebral disorder. Lancet 1984; 14: 86-9.
19. Moskowitz MA. Neurogenic inflammation in the pathophysiology and treatment of migraine. Neurology 1993; 43: S16-20.
20. Lance JW, Lambert GA, Goadsby PJ, Duckworth JW. Brainstem influences on the cephalic circulation: experimental data from cat and monkey of relevance to the mechanism of migraine. Headache 1983; 23: 258-65.
21. Moskowitz MA. Trigeminovascular system. Cephalalgia 1992; 12: 127.
22. Moskowitz MA. Basic mechanisms in vascular headache. Neurol Clin 1990; 8: 801-15.
23. Dimitriadou V, Buzzi MG, Moskowitz MA, Theoharides TC. Trigeminal sensory fiber stimulation induces morphological changes reflecting secretion in rat dura mater mast cells. Neuroscience 1991; 44: 97-112.
24. Dimitriadou V, Buzzi MG, Theoharides TC, Moskowitz MA. Ultrastructural evidence for neurogenically mediated changes in blood vessels of the rat dura mater and tongue following antidromic trigeminal stimulation. Neuroscience 1992; 48: 187-203.
25. Brain SD, Williams TJ. Inflammatory oedema induced by synergism between calcitonin gene-related peptide (CGRP) and mediators of increased vascular permeability. Br J Pharmacol 1985; 86: 855-60.
26. Arulmani U, VanDenBrink AM, Villalon CM, Saxena PR. Calcitonin gene-related peptide and its role in migraine pathophysiology. Eur J Pharmacol 2004; 500: 315-30.
27. Martin PR, Milech D, Nathan PR. Towards a functional model of chronic headaches: investigation of antecedents and consequences. Headache 1993; 33: 461-70.
28. Feindel W, Penfield W, McNaughton F. The tentorial nerves and localization of intracranial pain in man. Neurology 1960; 10: 555-63.
29. Hoskin KL, Zagami AS, Goadsby PJ. Stimulation of the middle meningeal artery leads to Fos expression in the trigeminocervical nucleus: a comparative study of monkey and cat. J Anat 1999; 194: 579-88.
30. Goadsby PJ, Hoskin KL. The distribution of trigeminovascular afferents in the nonhuman primate brain Macaca nemestrina: a c-fos immunocytochemical study. J Anat 1997; 190: 367-75.
31. Kerr FW. Atypical facial neuralgias: their mechanism as inferred from anatomic and physiologic data. Mayo Clin Proc 1960; 36: 254-60.
32. Goadsby PJ, Knight YE, Hoskin KL, Butler P. Stimulation of an intracranial trigeminally-innervated structure selectively increases cerebral blood flow. Brain Res 1997; 21: 247-52.
33. Goadsby PJ, Edvinsson L, Ekman R. Release of vasocactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminal system. Ann Neurol 1990; 23: 193-196.
34. Moskowitz MA, Cutrer FM. SUMATRIPTAN: a receptor-targeted treatment for migraine. Annu Rev Med 1993; 44: 145-54.
35. May A, Shepheard SL, Knorr M, Effert R, Wessing A, Hargreaves RJ, et al. Retinal plasma extravasation in animals but not in humans: implications for the pathophysiology of migraine. Brain 1998; 121: 1231-7.
36. Burstein R, Cutrer MF, Yarnitsky D. The development of cutaneous allodynia during a migraine attack clinical evidence for the sequential recruitment of spinal and supraspinal nociceptive neurons in migraine. Brain 2000; 123: 1703-9.
37. May A, Buchel C, Turner R, Goadsby PJ. Magnetic resonance angiography in facial and other pain: neurovascular mechanisms of trigeminal sensation. J Cereb Blood Flow Metab 2001; 21: 1171-6.
38. Ferrari MD, Odnik J, Bos KD, Malessey MJA, Bruyn GW. Neuroexcitatory plasma amino acids are elevated in migraine. Neurology 1990; 40: 1582-3.
39. Humphrey PP, Feniuk W, Perren MJ. Anti-migraine drugs in development: advances in serotonin receptor pharmacology. Headache 1990; 30 (Suppl. 1): 12-16.
40. Ophoff RA, van den Maagdenberg AM, Roon KI, Ferrari MD, Frants RR. The impact of pharmacogenetics for migraine. Eur J Pharmacol 2001; 9: 1-10.
41. 1D antagonists. J Med Chem 1994; 37: 2253-7
42. 1D receptor antagonist. Behav Brain Res 1996; 73: 157-61.
43. Saxena PR, Ferrari MD. 5-HT(1)-like receptor agonists and the pathophysiology of migraine. Trends Pharmacol Sci 1989; 10: 200-4.
44. 1B receptors. Naunyn Schmiedebergs Arch Pharmacol 1996; 353: 144-56.
45. 1B/1D receptors and α-adrenoceptors. Br J Pharmacol 1999; 1265: 385-94.
46. 1B receptors causes hypothermia in the guinea pig. Eur J Pharmacol 1997; 331: 169-74.
47. 1B receptor inverse agonist SB-224289, potently blocks terminal 5-HT autoreceptor function both in vitro and in vivo. Ann N Y Acad Sci 1998; 861: 270-1.
48. 1D receptors. Naunyn Schmiedebergs Arch Pharmacol 1997; 356: 312-20.
49. 1D receptor subtypes. Trends Pharmacol Sci 1996; 17: 103-5.
50. 1D receptor subtypes. Naunyn Schmiedebergs Arch Pharmacol 1996; 354: 237-44.
51. 1D beta receptor subtypes. Eur J Pharmacol 1995; 291: 9-15.
52. 1D receptors. Neuropharmacology 1997; 36: 513-24.
53. 1D agonists: potential new treatment for migraine without cardiovascular side effects. J Med Chem 1998; 41: 2180-3.
54. 1D receptor agonists as potential antimigraine agents. J Med Chem 1997; 24: 3501-3.
55. Mills A, Martin GR. Autoradiographic mapping of [3H]sumatriptan binding in cat brain stem and spinal cord. Eur J Pharmacol 1995; 280: 175-8.
56. Goadsby PJ, Knight Y. Inhibition of trigeminal neurones after intravenous administration of naratriptan through an action at 5-hydroxy-tryptamine (5-HT(1B/1D)) receptors. Br J Pharmacol 1997; 122: 918-22.
57. 1B/1D receptor agonist naratriptan on trigeminal versus spinal nociceptive responses. Cephalalgia 1998; 18: 659-63.
58. Johnson KW, Phebus LA, Cohen ML. Serotonin in migraine: theories, animal models and emerging therapies. Prog Drug Res 1998; 51: 219-44
59. 2B receptors: an early step in the generation of migraine headache? Eur J Neurosci 1996; 8: 959-67.
60. 2C receptor blockade? Life Sci 1994; 54: 641-4.
61. Fozard JR, Kalkman HO. 5-Hydroxytryptamine (5-HT) and the initiation of migriane: new perspectives. Naunyn-Schmiederberg's Arch Pharmacol 1994; 350: 225-229.
62. Fozard JR. The 5-hydroxytryptamine-nitric oxide connection: the key link in the initiation of migraine? Arch Int Pharmacodyn Ther 1995; 329: 111-9.
63. Ullmer C, Schmuck K, Kalkman HO, Lubbert H. Expression of serotonin receptor mRNAs in blood vessels. FEBS Lett 1995; 370: 215-21.
64. 2B receptor mediating contraction of longitudinal muscle in human small intestine. Br J Pharmacol 1995; 114: 1525-7.
65. 2B receptor antagonist. J Med Chem 1995; 38: 855-7.
66. 2C receptors. Br J Pharmacol 1995; 115: 622-8.
67. Thomas DR, Gager TL, Holland V, Brown AM, Wood MD. mchlorophenylpiperazine (mCPP) is an antagonist at the cloned human 5-HT2B receptor. NeuroReport 1996; 7: 1457-60.
68. 2A receptor affinity. J Med Chem 1995; 38: 28-33.
69. 2B) contractile receptor in the rat stomach fundus. J Med Chem 1996; 39: 2773-80.
70. De Vries P, Willems EW, Heiligers JP, Villalon CM, Saxena PR. Pharmacological aspects of experimental headache models in relation to acute antimigraine therapy. Eur J Pharmacol 1999; 375: 61-74.
71. Tfelt-Hansen P, Saxena PR, Dahlof C, Pascual J, Lainez M, Henry P, et al. Ergotamine in the acute treatment of migraine: a review and European consensus. Brain 2000; 123: 9-18.
72. Hieble JP. Adrenoceptor subclassification: an approach to improved cardiovascular therapeutics. Pharm Acta Helv 2000; 74: 163-71.
73. Ablad B, Dahlof C. Migraine and b-blockade: modulation of sympathetic neurotransmission. Cephalalgia 1986; 6: 7-13.
74. Koella WP. CNS-related (side) effects of β-blockers with special reference mechanisms of action. Eur J Clin Pharmacol 1985; 28: 5-63.
75. Stilberstein SD, Stilberstein MM. New concepts in the pathogenesis of headache. Part II. Pain Mgt 1990; 3: 334-342.
76. Ophoff RA, van Eijk R, Sandkuijl LA, Terwindt GM, Grubben CP, Haan J, et al. Genetic heterogeneity of familial hemiplegic migraine. Genomics 1994; 22: 21-6.
77. Ducros A, Joutel A, Vahedi K, Cecillon M, Ferreira A, Bernard E, et al. Mapping of a second locus for familial hemiplegic migraine to 1q21-q23 and evidence of further heterogeneity. Ann Neurol 1997; 42: 885-90.
78. Gardner K, Barmada MM, Ptacek LJ, Hoffman EP. A new locus for hemiplegic migraine maps to chromosome 1q31. Neurology 1997; 49: 1231-8.
79. Kovac K, Tothfaulsi L, Herman F, Magyar K. MAO activity, serotonin metabolism and aggregation of platelets from migraine patients. A preliminary study. Pol J Pharmacol Pharm 1998; 40: 691-695.
80. Lechner H, Ott E, Fazekas F, Pilger E. Evidence of enhance platelet aggregation and platelet sensitivity in migraine patients. Cephalalgia 1985; 5: 89-91.
81. Durham PL. CGRP receptor antagonists - a fresh approach to migraine therapy? N Engl J Med 2004; 350: 1073-75.
82. Edvinsson L. Blockade of CGRP receptors in the intracranial vasculature: a new target in the treatment of migraine. Cephalalgia 2004; 24: 611-522.
83. Doods H, Hallermayer G, Wu D, Entzeroth M, Rudolf K, Engel W, et al. Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist. Br J Pharmacol 2000; 129: 420-23.
84. Kapoor K, Arulmani U, Heiligers JP, Garrelds IM, Willems EW, Doods H, et al. Effects of the CGRP receptor antagonist BIBN4096BS on capsaicin induced carotid haemodynamic changes in anaesthetised pigs. Br J Pharmacol 2000; 140: 329-38.
85. Cutrer FM. Antiepileptic drugs: how they work in headache. Headache 2001; 41 (Suppl 1) S3-10.
86. Hering R, Kinitzky A. Sodium valproate in the prophylactic treatment of migraine. A double blind study versus placebo. Cephalalgia 1992; 12: 81-84.
87. Magnus L. Nonepileptic use of gabapentine. Epilepsia 1999; 40: S66-S72.
88. 7 receptor involved in the pathogenesis and prophylactic treatment of migraine? Eur J Pharmacol 2002; 439: 1-11.
89. Milan-Guerrero RO, Pineda-Lucatero AG, Hernanadez-Benjamin T, Tene CE, Pacheco MF. Naptha-methylhistamine. Safety and efficacy in migraine prophylaxis: phase I and phase II studies. Headache 2003; 43: 389-94.
90. Mahant N, Clouston PD, Lorentz IT. The current use of botulinium toxin. J Clin Neurosci 2000; 7: 389-94.
91. Schulte-Mattler WJ, Wieser T, Zierz S. Treatment of tension type headache with botulinium toxin: a pilot study. Eur J Med Res 1999; 4: 183-6.
92. Freund BJ, Schwartz M. Treatment of chronic cervical-associated headache with botulinium toxin A: a pilot study. Headache 2000; 40: 231-6.
93. Brin MF, Swope DM, O'Brien C, Abbasi S, Pogoda JM. Botox for migraine: double blind, placebo-controlled, region-specific evaluation. Cephalalgia 2000; 20: 421-22.
94. Cui M, Khanijou S, Rubino J, Aoki KR. Subcutaneous administration of botulinium toxin A reduces formalin-induced pain. Pain 2004; 107: 125-133.
95. Frei B, Kim MC, Ames BN. Ubiquinol-10 is an effective lipid soluble antioxidant at physiological concentrations. Proc Atl Acad Sci USA 1990; 87: 4879-83.
96. Ohhara H, Kanaide H, Yoshimura R, Okada M, Nakamura M. A protective effect of coenzyme Q10 on ischemia and reperfusion of the isolated perfused rat heart. J Mol Cell 1981; 13: 65-74.
97. Schoenen J, Lenaerts M, Bastings E. High dose riboflavin as a prophylactic treatment of migraine: results of an open label pilot study. Cephalalgia 1994; 14: 328-29.
98. Schoenen J, Jacquy, Lenaerts M. Effectiveness of high-dose riboflavin in migraine prophylaxis. A randomized controlled trial. Neurology 1998; 50: 466-70.
99. Rozen TD, Oshinsky ML, Gebeline CA, Bradely KC, Young WB, Silberstein SD. Open label trial of coenzyme Q10 as a migraine preventive. Cephalalgia 2002; 22: 137-141.
100. Moskowitz S, Saito K, Moskowitz MA. Neurogenically mediated leakage of plasma protein occurs from blood vessels in dura mater but not in brain. J Neurosci 1987; 7: 4129-36.
101. Buzzi MG, Moskowitz MA. The antimigraine drug, sumatriptan (GR43175), selectively blocks neurogenic plasma extravasation from blood vessels in dura mater. Br J Pharmacol 1990; 99: 202